Fig. 5
From: Decoding the evolutionary response to prostate cancer therapy by plasma genome sequencing
Genomic response in longitudinal cfDNA samples. a Total number of CNAs detected in longitudinal timepoints from 12 patients. b Mutation burden quantified from exome data of 12 patients, using all exonic mutations. c–h Plots of treatment schedules and therapeutic agents against changes in PSA levels (ng/mL) in 6 patients, with genomic copy number heatmaps and exome MAF plotted below for each timepoint. c, d CSPC patients with increasing mutations and CNAs. e, f CRPC patients with minor changes in mutations in CNAs during treatment. g, h CRPC patients with transient genomic response. Colors in mutation line plots represent different clones inferred by CITUP (the “Methods” section), while blue colors in PSA plots represent timepoints that were sampled for sequencing analysis